SCHEMBL31748645

SCHEMBL31748645

N/C(=N\O)c1cccc(O)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 10/20 0.59
PARP1 P09874 1/20 0.57
KDM4E B2RXH2 2/20 0.48
EGLN2 Q96KS0 1/20 0.48
CA12 O43570 3/20 0.48
CA2 P00918 3/20 0.48
CA9 Q16790 3/20 0.48
CA1 P00915 2/20 0.48
CA6 P23280 1/20 0.48
ALDH1A1 P00352 3/20 0.47
CA14 Q9ULX7 2/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
CA5A P35218 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
RECQL P46063 1/20 0.46
CA7 P43166 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8820938 1.00 KDM1A (0.59) KDM1APARP1KDM4EEGLN2CA12
SCHEMBL29478714 1.00 KDM1A (0.59) KDM1APARP1KDM4EEGLN2CA12
SCHEMBL750859 1.00 KDM1A (0.59) KDM1APARP1KDM4EEGLN2CA12
SCHEMBL750858 1.00 KDM1A (0.59) KDM1APARP1KDM4EEGLN2CA12
SCHEMBL31650872 0.78 F2 (0.55) KDM1ACA12CA2CA9CA1
SCHEMBL17730485 0.78 F2 (0.55) KDM1ACA12CA2CA9CA1
SCHEMBL2481256 0.78 F2 (0.55) KDM1ACA12CA2CA9CA1
SCHEMBL8312824 0.78 F2 (0.55) KDM1ACA12CA2CA9CA1
SCHEMBL2305031 0.77 KDM1A (0.49) KDM1ARECQL
SCHEMBL101968 0.77 GRIN2B (0.61) KDM1APARP1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B KDM1A 3533/4885PARP1 902/4885KDM4E 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.